文献速递白血病

附加基因突变可能完善2017年欧洲白血病网对60岁以下成人初诊急性髓系白血病的分类

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.
PubMed 文献 · Leukemia · 2020-05-27

在863例60岁以下、接受相同方案治疗的初诊急性髓系白血病患者中验证2017年欧洲白血病网(ELN)分类的预后价值,并在各遗传风险组内通过多变量模型识别可完善风险分层的附加基因突变。BCOR或SETBP1突变的非核心结合因子良好风险患者及IDH突变的不良风险患者预后居中;NPM1/WT1共突变及ZRSR2突变患者预后类似不良风险;FLT3-ITD高等位基因比值无论NPM1状态均 confer 不良而非中等风险,DNMT3A突变与极差生存相关。应用这些完善后,9%的当前良好风险患者和53%的当前中等风险患者被重新分类为不良风险组。

要点

  • BCOR或SETBP1突变的非核心结合因子良好风险患者及IDH突变的不良风险患者预后居中。
  • NPM1/WT1共突变及ZRSR2突变患者预后类似不良风险患者。
  • FLT3-ITD高等位基因比值无论NPM1状态均 confer 不良风险,DNMT3A突变与极差生存相关。

核心结论

  • 附加基因突变可完善2017年ELN分类,应用后9%的当前良好风险患者和53%的当前中等风险患者被重新分类为不良风险组,其生存与当前不良风险患者相似。
  • 4%的当前良好风险患者和9%的不良风险患者被重新分类为中等风险组。

研究设计与样本

  • 在863例60岁以下、接受相同治疗的初诊急性髓系白血病患者中验证2017年ELN分类的预后价值,这些患者来自Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology研究。
  • 在各ELN遗传风险组内通过多变量模型识别可完善2017年ELN风险分类的附加基因突变。

主要发现

  • BCOR或SETBP1突变的非核心结合因子良好风险患者及IDH突变的不良风险患者预后居中。
  • NPM1/WT1共突变患者及ZRSR2突变患者预后类似不良风险患者。
  • FLT3-ITD高等位基因比值无论NPM1突变状态均 confer 不良而非中等风险,DNMT3A突变与极差生存相关。
  • 应用这些完善后,9%的当前良好风险患者和53%的当前中等风险患者被重新分类为不良风险组,其生存与当前不良风险患者相似;4%的当前良好风险患者和9%的不良风险患者被重新分类为中等风险组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) have become an important tool to assess patients' prognosis and guide treatment. We tested the prognostic impact of the 2017 ELN classification in a large cohort of 863 AML patients aged <60 years similarly treated on Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology studies. Based on multivariable models within each ELN genetic-risk group, we identified additional gene mutations that may refine the 2017 ELN risk classification. BCOR- or SETBP1-mutated favorable-risk patients with non-core-binding factor AML and IDH-mutated adverse-risk patients had intermediate-risk outcomes. Outcomes of NPM1/WT1 co-mutated patients and those of ZRSR2-mutated patients resembled outcome of adverse-risk patients. Moreover, FLT3-ITDhigh allelic ratio conferred adverse rather than intermediate-risk irrespective of the NPM1 mutation status, and DNMT3A mutations associated with very poor survival. Application of these refinements reclassified 9% of current favorable-risk patients and 53% of current intermediate-risk patients to the adverse-risk group, with similar poor survival as current adverse-risk patients. Furthermore, 4% of current favorable-risk patients and 9% of adverse-risk patients were reclassified to the intermediate-risk group.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Eisfeld AK, Kohlschmidt J, Mims A, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years. Leukemia. 2020. PMID: 32461631. doi:10.1038/s41375-020-0872-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。